Pain and Schizophrenia

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2015 by University Hospital, Strasbourg, France
Sponsor:
Information provided by (Responsible Party):
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT01244542
First received: November 17, 2010
Last updated: June 18, 2015
Last verified: June 2015

November 17, 2010
June 18, 2015
August 2011
August 2016   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01244542 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pain and Schizophrenia
Pain and Schizophrenia
The aim of the investigators project is to explore the mechanisms of pain insensitivity in patients with schizophrenia, in order to prevent its invalidating consequences. The investigators will couple methods of experimental psychology with EEG and blood samplings, in order to distinguish the role of non-painful perception, attention, aversive effects, and pain expression, and the investigators will explore an original neurobiological hypothesis regarding the activation of opioid receptors.
Not Provided
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
  • Primary care and day clinic in Strasbourg, Erstein and Besançon
  • Healthy controls from or near Strasbourg, Erstein or Besançon.
  • Pain
  • Schizophrenia
Not Provided
  • 1-
    Patients with schizophrenia
  • 2-
    Healthy controls (controls matched with patients on age, sex and education level)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
107
August 2016
August 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with schizophrenia (criteria DSM IV) or healthy controls matched with patients on age, sex and education level
  • 18-55 years old

Exclusion Criteria:

  • Past history affecting CNS
  • Intake of psychotropic drugs, except for patients
  • Metabolic disorder affecting sensory processing (diabetes)
  • Intake of benzodiazepines
Both
18 Years to 55 Years   (Adult)
Yes
Contact: Anne GIERSCH, MD 03 88 11 64 71 giersch@alsace.u-strasbg.fr
France
 
NCT01244542
4706
No
Not Provided
Not Provided
University Hospital, Strasbourg, France
University Hospital, Strasbourg, France
Not Provided
Study Director: Anne Giersch, MD University Hospital, Strasbourg, France
University Hospital, Strasbourg, France
June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP